Research Analysts Set Expectations for AVIR Q1 Earnings

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) – Equities research analysts at William Blair issued their Q1 2026 EPS estimates for Atea Pharmaceuticals in a research report issued on Friday, March 7th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.40) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Atea Pharmaceuticals’ current full-year earnings is ($2.01) per share. William Blair also issued estimates for Atea Pharmaceuticals’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.59) EPS and FY2027 earnings at ($1.60) EPS.

Atea Pharmaceuticals (NASDAQ:AVIR) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05).

Atea Pharmaceuticals Price Performance

NASDAQ:AVIR opened at $2.92 on Monday. Atea Pharmaceuticals has a 52-week low of $2.75 and a 52-week high of $4.15. The stock has a fifty day simple moving average of $3.14 and a 200-day simple moving average of $3.33. The company has a market capitalization of $246.63 million, a PE ratio of -1.41 and a beta of 0.18.

Institutional Trading of Atea Pharmaceuticals

Several large investors have recently modified their holdings of the business. Intech Investment Management LLC purchased a new stake in Atea Pharmaceuticals in the 3rd quarter valued at approximately $36,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Atea Pharmaceuticals in the third quarter worth $37,000. Graham Capital Management L.P. purchased a new stake in shares of Atea Pharmaceuticals in the fourth quarter valued at $42,000. Millennium Management LLC acquired a new stake in shares of Atea Pharmaceuticals during the fourth quarter valued at $75,000. Finally, Zacks Investment Management purchased a new stake in Atea Pharmaceuticals during the 3rd quarter worth about $80,000. 86.67% of the stock is currently owned by institutional investors and hedge funds.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.